삼양바이오팜 is collaborating with the biotech venture Crosspoint Therapeutics to develop a gene therapy that selectively targets cancer cells. The approach combines Samyang Biopharm's next-generation gene delivery platform with Crosspoint's antibody technology.
On October 26, Samyang Biopharm announced that it signed a memorandum of understanding (MOU) with Crosspoint Therapeutics at the Samyang Discovery Center in Pangyo, Seongnam, South Korea, on October 23. The partnership aims to create a treatment that selectively targets cancer cells by integrating Samyang Biopharm's polymer-lipid-based gene delivery platform 'X-SENS' with Crosspoint's antibody platform 'StealthBody'.
Since August of last year, the two companies have been conducting preliminary evaluations using cell and animal models to explore the feasibility of combining their technologies. With this agreement, they plan to conduct technical feasibility verification and proof of concept (PoC) research over the next two years, and based on the results, they will consider non-clinical development and commercialization opportunities. The ultimate goal is to develop a treatment that precisely delivers short interfering RNA (siRNA) to cancer cells by attaching StealthBody, which recognizes specific tumor cells, to the X-SENS platform that carries nucleic acids.
X-SENS is an expanded platform designed by Samyang Biopharm that enhances its proprietary delivery vehicle 'SENS' by adding new components, allowing it to bind with various target substances (ligands). According to the company, X-SENS has lower immune responses and toxicity during repeated administration compared to existing lipid nanoparticles (LNPs) and can deliver nucleic acids to multiple tissues, including the liver, lungs, and spleen.
StealthBody is an 'Fc silencing' platform that modifies the tail (Fc) region of antibodies to prevent binding with immune cell receptors. This maintains the antibody's original targeting ability while reducing unnecessary immune activation and preventing the drug from entering normal cells, thereby minimizing side effects and enhancing target selectivity.
Kim Kyung-jin, CEO of Samyang Biopharm, stated, "Through this collaboration, we will develop next-generation gene therapies that directly target individual cancer cells beyond specific organ levels by combining StealthBody antibodies. We aim to demonstrate our technological superiority in the cancer gene therapy market by leveraging our platform's competitiveness."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.